Organon & Co.
Financials
Valuation Metrics
Organon & Co.'s Market Cap is $3.56B. At end of 2025 it was $1.86B. Ranked #1644 of 3,112 in US market (top 53%), #1061 of 1,667 on NYSE (top 64%), #94 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.56B | US#1,644/3,112 Sec#94/269 |
| Revenue | $6.16B | US#797/3,112 Sec#25/269 |
| Net Income | $246M | US#1,168/3,112 Sec#42/269 |
| Total Assets | $13.00B | US#835/3,112 Sec#25/269 |
| Net Assets | $903M | US#1,847/3,112 Sec#71/269 |
| Employees | 10,000 | US#602/3,112 Sec#14/269 |
| Value | ||
| P/E | 14.48x | US#638/3,112 Sec#24/269 |
| P/B | 3.94x | US#1,967/3,112 Sec#118/269 |
| PEG | 0.21x | US#327/3,112 Sec#15/269 |
| P/S | 0.58x | US#334/3,112 Sec#4/269 |
| EV/EBITDA | 7.96x | US#483/3,112 Sec#18/269 |
| FCF Yield | 17.24% | US#179/3,112 Sec#6/269 |
| Profitability | ||
| ROE | 27.24% | US#353/3,112 Sec#26/269 |
| ROA | 1.89% | US#1,641/3,112 Sec#68/269 |
| Op. Margin | 19.23% | US#967/3,112 Sec#42/269 |
| Revenue Growth | -3.50% | US#2,441/3,112 Sec#134/269 |
| Earnings Growth | 67.82% | US#461/3,112 Sec#21/269 |
| Financial Health | ||
| Debt Ratio | 1339.20% | US#2,844/3,112 Sec#252/269 |
| Total Debt | $8.57B | US#443/3,112 Sec#21/269 |
| FCF | $614M | US#775/3,112 Sec#32/269 |
| Cash | $1.12B | US#629/3,112 Sec#30/269 |
| Current Ratio | 1.97x | US#1,267/3,112 Sec#228/269 |
| Net Debt/EBITDA | 5.39x | US#2,100/3,112 Sec#85/269 |
| Dividend | ||
| Div. Yield | 0.62% | US#1,460/3,112 Sec#21/269 |
| Div. Growth | -70.65% | US—/3,112 Sec—/269 |
| Performance | ||
| 1Y Return | 40.15% | US#911/3,112 Sec#131/269 |
| 1M Return | 0.11% | US#1,632/3,112 Sec#74/269 |
| From 52W High | -0.26% | US#29/3,112 Sec#2/269 |
| 1Y MDD | -47.96% | US#2,321/3,112 Sec#177/269 |
| Trading | ||
| Volume | 1,361,229 shares | US#1,205/3,112 Sec#117/269 |
| Trading Value | $18M | US#2,011/3,112 Sec#153/269 |
| Per Share | ||
| EPS | $0.72 | US#1,738/3,112 Sec#58/269 |
| BPS | $2.89 | US#2,432/3,112 Sec#162/269 |
Company Info
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.